

Attn.: To whom it may concern at agencies in

RMS: DK

CMS: AT, DE, EL, IE, UK, BE, NL, LU, FR, PT, ES, BG, PL

Athens, 17/03/2015

Subject: Submission of Validation sequence of the Application Dossier(s) for Marketing Authorisation of Travoprost/ PharmaSwiss 40 micrograms/MI preservative free eye drops, solution in multi dose container DK/H/2475/001/DC

RMS: DK CMSs: AT, DE, EL, IE, UK, BE, NL, LU, FR, PT, ES, BG, PL

Dear Sirs,

We are pleased to submit the validation sequence of the Application Dossier(s) for a Decentralised Procedure which details are as follows:

Name of the medicinal product(s) (in the RMS): Travoprost PharmaSwiss
Pharmaceutical form(s) and strength(s): preservative free eye drops, solution

INN/active substance(s): Travoprost **ATC Code(s):** S01EE04

Legal Basis of the Application(s): Article 10(3) hybrid application

When appropriate, please indicate:

- Use of European Reference Medicinal Product **TRAVATAN 40 micrograms/ml eye drops, solution, Alcon Laboratories (UK) Ltd**
- If the strength(s) of the Reference MP differs between RMS/CMS
Yes
No
- If the pharmaceutical form(s) of the Reference MP differs between RMS/CMS
Yes
No
- If the indication(s) of the Reference MP differs between RMS/CMS
Yes
No

You will find enclosed the submission dossier as specified hereafter:

eCTD format

Sequence number: 0001

<1> media unit per application and <1> copy are provided.

We confirm that all future submissions for this specific product will be submitted in this same format (*NeeS format may be upgraded to eCTD later*).

Pharmathen S.A.

Headquarters: 44, Kifissias Avenue
151 25 Marousi, Athens Greece

T: +30 210 6604 300, F: +30 210 6666 749

info@pharmathen.com

The eCTD has passed the applicant's internal technical validation (all P/F criteria passed and all BP criteria have been fulfilled up to our best knowledge) using **EURS validator - Version 4 (4.0.0.009)**

We confirm that the electronic submission has been checked with an up-to-date and state-of-the-art virus checker. (**Symantec Endpoint Protection version: 12.1.4013.4013**).

- The relevant fees will be/have been paid according to national rules.

- The application is submitted through CESP to the RMS and the CMSs AT, DE, IE, UK, BE, NL, PT, ES, FR, LU since they are participating to the program. The submission in PL, BG and EL will be made via CD. The CESP-submission number is: CESP_Submission_

The dispatch list is appended (to RMS only).

The dispatch list will be forwarded to the RMS as soon as the application has been submitted to all CMS.

We, Pharmathen S.A. hereby certify that the dossier submitted to the RMS and CMS(s) are fully identical.

There are, however, some different **national** documents <cover letter><application form><specific national requirements> that are submitted to the relevant RMS/CMS only, **within** the eCTD/NeeS dossier

We, Pharmathen SA, also hereby certify that the content of the electronic submission is identical to the paper version.

Yours sincerely,

Regulatory Affairs Associate
44 Kifissias Ave., 15125 Marousi Attica , Greece
T: | F:
email: | web:www.pharmathen.com

For technical validation issues: Mrs _____ at _____